Phio Pharmaceuticals to present RNAi immunotherapy research at ITOC 2025

Phio Pharmaceuticals Corp. is a clinical-stage siRNA biotechnology company developing therapeutics using its proprietary INTASYL^® gene silencing technology to eliminate cancer. Phio  announced that podium presentations will be given on its two lead INTASYL product candidates, PH-762 and PH-894.

The ITOC conference provides a unique platform for the exchange of latest findings in immunotherapy of cancer to advance oncology drug development and delivery.

Melissa Maxwell, Phio’s Director of Research and Program Management, was awarded two speaker presentations, as follows:

Plenary Session 3: New Targets and New Leads
Date and Time: April 3, 2025, 16.30 – 16.45 PM (CEST) 

Title: Targeting PD-1 with self-delivering RNAi: preclinical advances and ongoing clinical evaluation in intratumoral Immunotherapy

PH-762, an INTASYL siRNA compound targeting PD-1, is being evaluated in an ongoing clinical trial (NCT 06014086) as a neoadjuvant intratumoral therapy for cutaneous malignancies, demonstrating promising preclinical efficacy, favorable tolerability, and the potential to enhance immune responses while minimizing systemic side effects.

Plenary Session 11: What Cellular Therapies Need to Work
Date and Time: April 5, 2025, 12.15 – 12.30 PM (CEST)

Title: Silencing BRD4 to increase NK cell activity for adoptive cell therapy: a novel self- delivering RNAi approach

PH-894, an INTASYL siRNA compound, selectively silences BRD4, a key regulator of gene expression. PH-894 enhances NK cell activation and proliferation without off-target effects, presenting a promising strategy to improve adoptive cell therapy.